Merck, Pfizer, Verastem enter trial collaboration in ovarian cancer
Merck KGAA and Pfizer Inc. are collaborating with Verastem Inc. to evaluate avelumab and Verastem’s defactinib (VS6063) as a combination therapy for advanced ovarian cancer.
- Trial Collaborations
- R&D (No Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com